BR112019026916A2 - composições de ésteres de ácido canabidiólico e usos das mesmas - Google Patents
composições de ésteres de ácido canabidiólico e usos das mesmas Download PDFInfo
- Publication number
- BR112019026916A2 BR112019026916A2 BR112019026916-9A BR112019026916A BR112019026916A2 BR 112019026916 A2 BR112019026916 A2 BR 112019026916A2 BR 112019026916 A BR112019026916 A BR 112019026916A BR 112019026916 A2 BR112019026916 A2 BR 112019026916A2
- Authority
- BR
- Brazil
- Prior art keywords
- branched
- linear
- cbda
- disease
- compound according
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
- C07C69/94—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of polycyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of six-membered aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
- C07C69/12—Acetic acid esters
- C07C69/16—Acetic acid esters of dihydroxylic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
- C07C69/22—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety
- C07C69/28—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety esterified with dihydroxylic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Otolaryngology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762522243P | 2017-06-20 | 2017-06-20 | |
| US62/522,243 | 2017-06-20 | ||
| PCT/IL2018/050678 WO2018235079A1 (en) | 2017-06-20 | 2018-06-20 | CANNABIDIOLIC ACID ESTER COMPOSITIONS AND USES THEREOF |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112019026916A2 true BR112019026916A2 (pt) | 2020-06-30 |
Family
ID=62875079
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112019026916-9A BR112019026916A2 (pt) | 2017-06-20 | 2018-06-20 | composições de ésteres de ácido canabidiólico e usos das mesmas |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11440870B2 (https=) |
| EP (1) | EP3509638B1 (https=) |
| JP (1) | JP2020524679A (https=) |
| CN (2) | CN121534035A (https=) |
| AU (1) | AU2018287018B2 (https=) |
| BR (1) | BR112019026916A2 (https=) |
| CA (1) | CA3067512A1 (https=) |
| DK (1) | DK3509638T3 (https=) |
| ES (1) | ES2909350T3 (https=) |
| MX (1) | MX389847B (https=) |
| PT (1) | PT3509638T (https=) |
| WO (1) | WO2018235079A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10239808B1 (en) | 2016-12-07 | 2019-03-26 | Canopy Holdings, LLC | Cannabis extracts |
| EP3509638B1 (en) | 2017-06-20 | 2022-01-12 | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. | Cannabidiolic acid esters compositions and uses thereof |
| CA3089994A1 (en) | 2018-01-31 | 2019-08-08 | Canopy Holdings, LLC | Hemp powder |
| WO2020077153A1 (en) | 2018-10-10 | 2020-04-16 | Canopy Holdings, LLC | Synthesis of cannabigerol |
| WO2020136648A1 (en) * | 2018-12-25 | 2020-07-02 | Epm Group Inc. | Cannabidiolic acid esters for cosmetic or edible compositions |
| US12403114B2 (en) | 2019-03-12 | 2025-09-02 | Epm (Ip), Inc. | Cannabinoid acid ester compositions and uses thereof |
| WO2021034403A1 (en) | 2019-08-22 | 2021-02-25 | Epm Group, Inc. | Cannabinoid acid ester compositions and uses thereof |
| WO2021137224A1 (en) * | 2020-01-01 | 2021-07-08 | Epm Group, Inc. | Cannabidiolic acid esters for treating muscular dystrophy |
| IL275108A (en) * | 2020-06-03 | 2022-01-01 | Epm Ip Inc | Abnormal acid cannabidiol (abn-cbd) derivatives and their uses |
| WO2022103639A1 (en) * | 2020-11-16 | 2022-05-19 | Orcosa Inc. | Methods of treating autoimmune or inflammatory conditions with cannabidiol or its derivatives/analogs |
| US11672761B2 (en) | 2020-11-16 | 2023-06-13 | Orcosa Inc. | Rapidly infusing platform and compositions for therapeutic treatment in humans |
| IL303739A (en) * | 2020-12-24 | 2023-08-01 | Buzzelet Development And Technologies Ltd | Compositions including cannabinoid esters |
| US20230066947A1 (en) * | 2021-08-04 | 2023-03-02 | Max Hammond | Method for the augmentation of substance abuse therapies using cannabinoid formulations |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2318468A1 (fr) | 1975-07-17 | 1977-02-11 | Jaeger | Dispositif electronique d'enregistrement et de lecture de donnees concernant differents parametres au cours d'un cycle predetermine, fonction de l'un desdits parametres |
| US5342971A (en) | 1992-12-29 | 1994-08-30 | The Australian National University | Process for the preparation of dibenzo[b,d]pyrans |
| ATE277921T1 (de) | 1998-05-04 | 2004-10-15 | Univ Connecticut | Selektiv auf den cb2-rezeptor wirkende cannabinoide |
| IL136839A (en) | 2000-06-16 | 2006-12-10 | Yissum Res Dev Co | Pharmaceutical compositions comprising cannabidiol derivatives, and processes for the preparation of same |
| JP2008502690A (ja) | 2004-06-15 | 2008-01-31 | アンドリュー シァン チェン， | リン脂質組成物ならびにその調製方法および使用方法 |
| CA2623723A1 (en) | 2005-09-29 | 2007-04-12 | Amr Technology, Inc. | Process for production of delta-9-tetrahydrocannabinol |
| CN101384012B (zh) * | 2008-10-22 | 2012-05-23 | 华为终端有限公司 | 系统端和终端的交互媒体文档更新方法及装置 |
| DE102009019322A1 (de) * | 2009-04-30 | 2010-11-11 | The Health Concept Gmbh | Verfahren zur Herstellung von Synthetischen Cannabinoiden |
| GB2478595B (en) | 2010-03-12 | 2018-04-04 | Gw Pharma Ltd | Phytocannabinoids in the treatment of glioma |
| GB2494461A (en) | 2011-09-12 | 2013-03-13 | Gw Pharma Ltd | Phytocannabinoids for use in the treatment of invasive cancers or metastases |
| GB2515312A (en) | 2013-06-19 | 2014-12-24 | Gw Pharma Ltd | The use of phytocannabinoids in the treatment of ovarian carcinoma |
| EP2842933B1 (de) * | 2013-09-03 | 2015-07-29 | Symrise AG | Mischungen cannabinoider Verbindungen, deren Herstellung und Verwendung |
| US9701618B2 (en) * | 2014-04-16 | 2017-07-11 | Vivacell Biotechnology España S.L. | Cannabidiol quinone derivatives |
| GB2527590A (en) | 2014-06-27 | 2015-12-30 | Otsuka Pharma Co Ltd | Active pharmaceutical ingredient (API) comprising cannabinoids for use in the treatment of cancer |
| GB2531283A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabidiols in the treatment of degenerative skeletal muscle diseases |
| EP3061450A1 (de) | 2015-02-26 | 2016-08-31 | Symrise AG | Mischungen cannabinoider Verbindungen, deren Herstellung und Verwendung |
| GB2551987A (en) | 2016-07-01 | 2018-01-10 | Gw Res Ltd | Oral cannabinoid formulations |
| CN106810426B (zh) | 2016-12-29 | 2020-05-08 | 暨明医药科技（苏州）有限公司 | 一种大麻二酚的合成方法 |
| EP3509638B1 (en) | 2017-06-20 | 2022-01-12 | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. | Cannabidiolic acid esters compositions and uses thereof |
| WO2019234728A1 (en) | 2018-06-04 | 2019-12-12 | Al&Am Pharmachem Ltd. | Cannabinolic acid derivatives and uses thereof |
-
2018
- 2018-06-20 EP EP18739958.9A patent/EP3509638B1/en active Active
- 2018-06-20 BR BR112019026916-9A patent/BR112019026916A2/pt not_active Application Discontinuation
- 2018-06-20 ES ES18739958T patent/ES2909350T3/es active Active
- 2018-06-20 AU AU2018287018A patent/AU2018287018B2/en active Active
- 2018-06-20 CN CN202511437638.6A patent/CN121534035A/zh active Pending
- 2018-06-20 PT PT187399589T patent/PT3509638T/pt unknown
- 2018-06-20 WO PCT/IL2018/050678 patent/WO2018235079A1/en not_active Ceased
- 2018-06-20 CA CA3067512A patent/CA3067512A1/en active Pending
- 2018-06-20 MX MX2019015311A patent/MX389847B/es unknown
- 2018-06-20 US US16/343,050 patent/US11440870B2/en active Active
- 2018-06-20 JP JP2019570108A patent/JP2020524679A/ja active Pending
- 2018-06-20 DK DK18739958.9T patent/DK3509638T3/da active
- 2018-06-20 CN CN201880041597.0A patent/CN111032088A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2020524679A (ja) | 2020-08-20 |
| EP3509638A1 (en) | 2019-07-17 |
| AU2018287018A1 (en) | 2020-01-30 |
| AU2018287018B2 (en) | 2022-04-28 |
| WO2018235079A1 (en) | 2018-12-27 |
| ES2909350T3 (es) | 2022-05-06 |
| EP3509638B1 (en) | 2022-01-12 |
| CA3067512A1 (en) | 2018-12-27 |
| PT3509638T (pt) | 2022-03-02 |
| DK3509638T3 (da) | 2022-04-11 |
| CN121534035A (zh) | 2026-02-17 |
| US20200115317A1 (en) | 2020-04-16 |
| MX2019015311A (es) | 2022-02-02 |
| CN111032088A (zh) | 2020-04-17 |
| MX389847B (es) | 2025-03-20 |
| US11440870B2 (en) | 2022-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112019026916A2 (pt) | composições de ésteres de ácido canabidiólico e usos das mesmas | |
| Pertwee et al. | Cannabidiolic acid methyl ester, a stable synthetic analogue of cannabidiolic acid, can produce 5‐HT1A receptor‐mediated suppression of nausea and anxiety in rats | |
| ES2708808T3 (es) | Tetrahidrocannabivarina para uso en el tratamiento de náuseas y vómitos | |
| US8148354B2 (en) | Use of 20(S)-protopanaxadiol in manufacture of antidepressants | |
| CN102000072A (zh) | 偶联有一氧化氮供体的抗肿瘤天然药物及其医药用途 | |
| CN101848711A (zh) | 一种药物组合物及其在制备治疗脑血管病药物中的应用 | |
| CN106102737A (zh) | 色甘酸衍生物以及成像和治疗的相关方法 | |
| CN109748881A (zh) | 胱硫醚-γ-裂合酶(CSE)抑制剂 | |
| CN1592616A (zh) | 与神经甾体活性降低相关的疾病的治疗中的gaba增强剂 | |
| US20210369698A1 (en) | Treating Dermatological Conditions with Chloroquine and/or Hydroxychloroquine | |
| CN103948600A (zh) | 用于治疗特定癌症的包含rdea119/bay869766的药物组合 | |
| JP2007526328A (ja) | 単独および抗うつ薬と組み合わせた形のＣｏｘ−２阻害剤によって精神障害を治療または予防するための方法および組成物 | |
| JP2018177739A (ja) | Ｔｒｐａ１活性化剤 | |
| Verma et al. | A review of patents on therapeutic potential and delivery of hydroge n sulfide | |
| Class et al. | Patent application title: CANNABIDIOLIC ACID ESTERS COMPOSITIONS AND USES THEREOF Inventors: Raphael Mechoulam (Jerusalem, IL) Linda Parker (Campbell River, British Columbia, CA) Roger Pertwee (Aberdeen, Scotland, GB) Aron Weller (Shoham, IL) Joseph Tam (Jerusalem, IL) Christeen Haj (Nazareth Hit, IL) Reem Smoum (Jerusalem, IL) | |
| CN107446010A (zh) | 一种红霉素衍生物及其制备方法和应用 | |
| JP2005538098A (ja) | ヘムオキシゲナーゼレベルの上昇を必要とする治療上の処置におけるレインの使用 | |
| HK40028173A (en) | Cannabidiolic acid esters compositions and uses thereof | |
| Nakamura et al. | Modification of cocaine‐induced behavioral and neurochemical effects by serotonin1A receptor agonist/antagonist in mice | |
| CN106038521A (zh) | 一种丹皮酚同系物的抗炎活性及其制剂应用 | |
| CN104586835B (zh) | 穿心莲内酯的医药用途 | |
| US3433875A (en) | The improvement of mental performance with potassium n-acetyl dl aminosuccinate | |
| CN110003157A (zh) | 一种具有抗焦虑作用的新型黄酮类化合物及其应用 | |
| CN112190570B (zh) | 天麻来源衍生物在制备治疗急性或慢性疼痛药物中的用途 | |
| CN107158020A (zh) | 一种眼科用药物组合物及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |